Arterial stiffness progression in metabolic dysfunction-associated fatty liver disease subtypes: A prospective cohort study

被引:1
|
作者
Liu, Lei [1 ]
Zhou, Yufu
Deng, Shuwen [1 ]
Yuan, Ting [1 ]
Yang, Saiqi [1 ]
Zhu, Xiaoling [1 ]
Wang, Changfa [2 ]
Wang, Yaqin [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Hlth Management Ctr, Dept Gastroenterol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Gen Surg Dept, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
关键词
Arterial stiffness; Brachial ankle pulse wave velocity (baPWV); Metabolic dysfunction-associated fatty liver (MAFLD); Diabetes; ASIA-PACIFIC REGION; CARDIOVASCULAR-DISEASE; RISK-FACTORS;
D O I
10.1016/j.numecd.2024.03.030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: We aimed to investigate the correlation and to explore which MAFLD subtypes have the greatest influence on progression of arterial stiffness risk. Methods and results: Using data from a health examination-based cohort, a total of 12,129 participants who underwent two repeated health examinations that included brachial-ankle pulse wave velocity (baPWV) from 2012 to 2020 were enrolled. Participants were separated into non-MAFLD, overweight/obese (OW-MAFLD), lean/normal weight (lean-MAFLD) and diabetes (DM-MAFLD) groups. Among the participants with a median follow-up of 2.17 years, 4511 (37.2%) participants had MAFLD at baseline, among which 3954 (87.7%), 123 (2.7%), and 434 (9.6%) were OW-, lean- and DM-MAFLD, respectively. Analyses using linear regression models confirmed that compared with the non-MAFLD group, the elevated baPWV change rates (cm/s/ year) were 12.87 (8.81-16.94), 25.33 (7.84-42.83) and 38.49 (27.88-49.10) in OW, lean and DM -MAFLD, respectively, while the increased change proportions (%) were 1.53 (1.10-1.95), 3.56 (1.72-5.40) and 3.94 (2.82-5.05), respectively. Similar patterns were observed when these two baPWV parameters were transformed in the form of the greatest increase using Cox proportional hazards model analyses. Furthermore, the risk of arterial stiffness progression across MAFLD subtypes presented a significant, gradient, inverse relationship in the order of DM-, lean-, OW with metabolic abnormalities (MA)-, and OW without MA-MAFLD. Conclusion: MAFLD, especially DM-MAFLD and lean-MAFLD, was significantly associated with arterial stiffness progression, providing evidence that stratification screening and surveillance strategies for CVD risk have important clinical implications. (c) 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1890 / 1900
页数:11
相关论文
共 50 条
  • [31] Impact of visceral adiposity for coronary artery calcification progression in patients with metabolic dysfunction-associated fatty liver disease; multicenter cohort study
    Kang, Min Kyu
    Kim, KyeWhon
    Song, Jung Eun
    Park, Jung Gil
    JOURNAL OF HEPATOLOGY, 2023, 78 : S645 - S646
  • [32] Metabolic dysfunction-associated fatty liver disease: a year in review
    Alharthi, Jawaher
    Gastaldelli, Amalia
    Cua, Ian Homer
    Ghazinian, Hasmik
    Eslam, Mohammed
    CURRENT OPINION IN GASTROENTEROLOGY, 2022, 38 (03) : 251 - 260
  • [33] Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?
    Feng, Gong
    Byrne, Christopher D.
    Targher, Giovanni
    Wang, Fudi
    Zheng, Ming-Hua
    LIVER INTERNATIONAL, 2022, 42 (07) : 1496 - 1502
  • [34] Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
    Bhopale, Kamlesh K.
    Srinivasan, Mukund P.
    LIVERS, 2023, 3 (04): : 597 - 617
  • [35] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi Yiwen
    Fan Jiangao
    中华医学杂志英文版, 2022, 135 (09) : 1009 - 1018
  • [36] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi, Yiwen
    Fan, Jiangao
    CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1009 - 1018
  • [37] Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease
    Perdomo, Carolina M.
    Nunez-Cordoba, Jorge M.
    Ezponda, Ana
    Mendoza, Francisco J.
    Ampuero, Javier
    Bastarrika, Gorka
    Fruhbeck, Gema
    Escalada, Javier
    FRONTIERS IN MEDICINE, 2022, 9
  • [38] Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
    Fouad, Yasser
    Alboraie, Mohamed
    Shiha, Gamal
    HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 827 - 833
  • [39] The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
    Goya, Takeshi
    Imoto, Koji
    Tashiro, Shigeki
    Aoyagi, Tomomi
    Takahashi, Motoi
    Kurokawa, Miho
    Suzuki, Hideo
    Tanaka, Masatake
    Kato, Masaki
    Kohjima, Motoyuki
    Ogawa, Yoshihiro
    GASTROENTEROLOGY INSIGHTS, 2022, 13 (01) : 20 - 26
  • [40] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51